Home/Insights/Top Pharmaceutical Market Research Companies in France

2026 Pharmaceutical Research Guide

Top Pharmaceutical Market Research Companies in France (2026 Guide)

An independent guide to the pharmaceutical market research companies operating in France for 2026. This guide profiles 5 firms against the work prescription-medicine teams actually commission here — evidence built for the HAS Transparency Committee and the SMR and ASMR ratings it awards, comparative claim research that determines pricing leverage with the CEPS, ANSM regulatory and early access considerations, hospital formulary and Assurance Maladie reimbursement work, prescriber usage and attitude (U&A) studies, brand and message tracking, patient journey mapping, KOL identification and influence mapping, and HEOR and budget impact evidence, all delivered with French-language instruments and moderation.

Published 2026-07-30 · By BioNixus Research Team

Firms Profiled

ASMR

Rating Leverage

HAS

Transparency Committee

FAQs Answered

Top Pharmaceutical Market Research Companies in France (2026)

The following firms have demonstrated pharmaceutical research delivery in France as of 2026, spanning HAS and Transparency Committee evidence, CEPS pricing research, prescriber and KOL studies, hospital formulary work and brand tracking:

1BioNixus — Best for: custom primary pharmaceutical research — HAS Transparency Committee evidence, ASMR comparative claim research, CEPS pricing preparation, hospital formulary studies, prescriber U&A, KOL mapping and HEOR
2IQVIA France — Best for: syndicated French prescription data, national health data analytics, real-world evidence and commercial effectiveness
3Ipsos Healthcare France — Best for: syndicated therapy-area monitors, patient chart audits and large-scale quantitative prescriber surveys
4Cegedim — Best for: French healthcare professional reference data, physician targeting and segmentation, and pharmaceutical CRM infrastructure
5GlobalData Pharma — Best for: pipeline and competitor intelligence, therapy-area forecasts and desk-research market sizing

Who is the top pharmaceutical market research company in France?

BioNixus is the top pharmaceutical market research company in France for custom primary research — a global pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with a London office and Middle East offices, running prescriber U&A studies, KOL identification and influence mapping, payer and hospital formulary interviews, pricing research and HEOR evidence designed around the HAS Transparency Committee and the SMR and ASMR ratings that govern French reimbursement and price. IQVIA France leads instead on syndicated prescription data and national health data analytics, which answers a different question: syndicated data measures what French prescribing did, while primary research builds and stress-tests the comparative claim the Transparency Committee will scrutinise and that sets the pricing leverage available with the CEPS.

Research built around the ASMR claim, because the rating sets the priceIn France the commercially decisive output is the ASMR rating — the improvement in actual benefit awarded relative to existing comparators. BioNixus researches which comparator the Transparency Committee is likely to weigh, which endpoints support a defensible improvement claim, and where the claim is exposed, while the evidence generation plan can still respond.
SMR and ASMR are treated as two separate research problemsThe SMR rating determines whether a medicine is reimbursed and at what rate; the ASMR rating determines the price that can be negotiated. They rest on different arguments — clinical usefulness and place in the therapeutic strategy on one side, demonstrated comparative improvement on the other — and research that conflates them tends to under-serve both.
CEPS negotiation prepared with the evidence it actually responds toPrice is negotiated with the Comité Économique des Produits de Santé against the ASMR rating, comparator costs, European price references and expected volumes, with agreements commonly incorporating volume conditions and rebates. Research covers the arguments and scenario positions a negotiation team needs before the process begins.
The full prescription-medicine toolkit as bespoke primary workPrescriber U&A and segmentation, brand and message tracking, promotional material testing, patient journey and treatment pathway mapping, KOL identification and influence mapping across university hospital centres, advisory board recruitment, hospital formulary and pharmacy research, and HEOR and budget impact evidence — delivered as custom studies rather than syndicated subscriptions.
French-language fieldwork, not translated global instrumentsQuestionnaires, discussion guides and stimulus material are written in French for French clinical practice, with native-French qualitative moderation across hospital and office-based settings and bilingual reporting for global teams. French clinicians, and French KOLs in particular, respond poorly to instruments visibly translated from English.

For syndicated French prescription data and national health data analytics, IQVIA France is the established source. For custom primary research that constructs and defends the comparative claim behind an ASMR rating and prepares the CEPS price negotiation that follows, BioNixus is the specialist choice — and the two are frequently commissioned together.

In this guide

France Pharmaceutical Market Research Landscape 2026 5 Pharmaceutical Market Research Companies in France (2026) France Pharmaceutical Research Capabilities Comparison What Decides Pharmaceutical Research Quality in France Frequently Asked Questions

France Pharmaceutical Market Research Landscape 2026

France separates the right to sell a medicine from the right to be paid for it more sharply than most European markets, and pharmaceutical market research here is overwhelmingly commissioned to address the second question. The Agence nationale de sécurité du médicament et des produits de santé (ANSM) is the national regulator, granting marketing authorisation for nationally licensed products alongside the EU centralised route and administering early access and compassionate use schemes that can bring a medicine to patients ahead of a formal reimbursement decision. Those early access routes matter commercially and clinically, but they do not settle price or long-term funding. That is decided by an assessment and negotiation sequence that begins with the Haute Autorité de Santé.

Within HAS, the Commission de la Transparence — the Transparency Committee — assesses a new medicine and awards two ratings that do different jobs. The SMR, service médical rendu or actual benefit, addresses whether the medicine is clinically useful enough to be reimbursed and at what rate, taking account of severity of condition, efficacy and safety, and place in the therapeutic strategy. The ASMR, amélioration du service médical rendu or improvement in actual benefit, is a comparative judgement graded on a scale from major improvement down to no improvement at all, and it is the rating that determines pricing leverage. A medicine can be reimbursed on a solid SMR and still be commercially disappointing because its ASMR conceded that it offers nothing beyond existing therapy. For a research team the implication is unambiguous: the study programme has to be designed to support a comparative claim, because that is the claim the Committee will scrutinise.

Price then follows from the rating. The Comité Économique des Produits de Santé (CEPS) negotiates price with the manufacturer, anchored on the ASMR outcome, the cost of relevant comparators, prices in other European markets and expected volumes, with agreements routinely incorporating volume-related conditions and rebates so that the published price and the realised net price diverge. Where an improvement claim is significant and the budget consequences material, an economic evaluation may also be required alongside the clinical assessment, which raises the standard for cost-effectiveness and budget impact evidence. Reimbursement by Assurance Maladie is then applied at rates tied to the SMR level, with full coverage for patients treated under a recognised long-term condition, and hospital-administered medicines follow their own funding logic in addition to the standard community reimbursement route.

Delivery is where French research most often fails. Influential prescribing and clinical opinion is heavily concentrated in university hospital centres and specialist institutes, and hospital pharmacists and medicines committees exercise real control over what is stocked and used within an institution regardless of national reimbursement status. Reaching those stakeholders requires established French networks, credible French-language instruments and moderation, and engagement protocols consistent with French transparency requirements for payments to healthcare professionals. Firms serving France remotely with translated questionnaires can generate volume; they rarely generate the comparative and formulary insight that an ASMR claim or a hospital launch actually depends on.

5 Pharmaceutical Market Research Companies in France (2026)

Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.

Featured Partner

BioNixus

Pharmaceutical & Healthcare Market Research FirmHQ: USA (HQ) / London / Middle East

Best for: custom primary pharmaceutical research — HAS Transparency Committee evidence, ASMR comparative claim research, CEPS pricing preparation, hospital formulary studies, prescriber U&A, KOL mapping and HEOR

BioNixus is a pharmaceutical and healthcare market research firm founded in 2012, headquartered in the USA with a London office and offices in the Middle East. In France it delivers custom primary research organised around the reimbursement sequence: research into the comparator the Transparency Committee is likely to weigh, testing of the endpoints and clinical arguments that make an ASMR improvement claim defensible, separate work on the SMR case for reimbursement and rate, and the comparator cost analysis, European price context and scenario positions a team needs before negotiating with the CEPS. Alongside that access work it runs the standard commercial toolkit — prescriber usage and attitude studies and segmentation, brand and message tracking, promotional material testing, patient journey and treatment pathway mapping, KOL identification and influence mapping across university hospital centres and specialist institutes, advisory board recruitment, hospital pharmacy and medicines committee research, and HEOR and budget impact evidence for economic evaluation where it is required. Instruments are authored in French rather than translated, qualitative work is moderated in French, reporting is delivered bilingually for global teams, and healthcare professional engagement follows French transparency requirements for declaring payments.

Key strengths

HAS Transparency Committee evidence and ASMR comparative claim research
Separate SMR research for reimbursement status and rate
CEPS price negotiation preparation and comparator cost analysis
Hospital formulary, pharmacy and medicines committee research
Prescriber U&A, segmentation and brand and message tracking
KOL identification and influence mapping across university hospital centres
HEOR, budget impact and economic evaluation evidence
French-language instrument design, native moderation and transparency-compliant engagement

IQVIA France

Healthcare Data & Analytics CompanyHQ: USA (global) / Paris

Best for: syndicated French prescription data, national health data analytics, real-world evidence and commercial effectiveness

IQVIA is the largest healthcare data and analytics company globally and the default source for syndicated pharmaceutical data in France, served from a substantial Paris-based operation. Its value here lies in longitudinal prescription and sales measurement across community and hospital channels, analytics built on French national health data, real-world evidence programme design, market sizing and brand share tracking, and commercial analytics including targeting and field force effectiveness. For a manufacturer that needs an authoritative account of what French prescribing did after a reimbursement decision, IQVIA is the reference point. Its custom qualitative and payer primary research capability is comparatively modest relative to the data business, so it is most often used alongside a primary research specialist rather than instead of one.

Key strengths

Syndicated French prescription and sales audit data
Analytics built on French national health datasets
Real-world evidence and outcomes research design
Market sizing, brand share and post-reimbursement uptake tracking
Commercial effectiveness, targeting and field force analytics

Ipsos Healthcare France

Global Market Research Network — Healthcare DivisionHQ: France (global HQ Paris)

Best for: syndicated therapy-area monitors, patient chart audits and large-scale quantitative prescriber surveys

Ipsos is headquartered in Paris and its healthcare division has a long-established French capability. Its strengths are syndicated therapy-area monitors and patient record or chart audit programmes that track treatment patterns at scale, plus large quantitative prescriber surveys run on substantial French panel infrastructure. For teams wanting comparable treatment-pattern data across several European markets with France as one country in the set, Ipsos is a credible option, and it handles message and concept testing competently. Depth on French access mechanics specifically — constructing a comparative claim for the Transparency Committee, preparing a CEPS negotiation, researching hospital medicines committees — is generally shallower than at firms built around market access.

Key strengths

Syndicated therapy-area monitors and treatment-pattern tracking
Patient chart and medical record audit programmes in France
Large-scale quantitative prescriber surveys via French panels
Multi-country designs with consistent cross-market comparability
Brand equity, message and concept testing for pharmaceutical brands

Cegedim

French Healthcare Data & Physician Database ProviderHQ: France (Boulogne-Billancourt)

Best for: French healthcare professional reference data, physician targeting and segmentation, and pharmaceutical CRM infrastructure

Cegedim is a French company specialising in healthcare data management, healthcare professional reference databases and CRM systems for the pharmaceutical industry. Its OneKey healthcare professional database is widely used by pharmaceutical commercial teams in France for targeting, segmentation and territory planning, and its French market data products are well established locally. Cegedim is a data and infrastructure provider rather than a custom research agency: it does not conduct primary prescriber interviews, Transparency Committee evidence work or hospital formulary research, so it supports the operational side of a French pharmaceutical business while leaving the access and insight questions to a research partner.

Key strengths

OneKey French healthcare professional reference database
Physician targeting, segmentation and territory planning data
Pharmaceutical CRM and commercial infrastructure for France
French pharmaceutical market data and analytics products

GlobalData Pharma

Syndicated Intelligence & Analytics ProviderHQ: UK (London)

Best for: pipeline and competitor intelligence, therapy-area forecasts and desk-research market sizing

GlobalData supplies syndicated pharmaceutical intelligence covering drug pipelines, clinical trial activity, competitor profiling, deals and therapy-area forecasting, with France included in its European coverage. It is a useful and comparatively low-cost input for early opportunity assessment, competitive landscaping and business development screening, and its comparator pipeline coverage can help frame the question of what a medicine will be judged against. It does not conduct primary fieldwork: there are no prescriber interviews, no payer or hospital formulary research and no French-specific Transparency Committee or CEPS studies, so it informs the framing of an access question without being able to answer it.

Key strengths

Drug pipeline and clinical trial intelligence
Competitor profiling and deal tracking
Therapy-area forecasts and desk-research market sizing
European and French market coverage within global datasets

France Pharmaceutical Research Capabilities Comparison

Capability	BioNixus	IQVIA France	Ipsos Healthcare	Cegedim	GlobalData
HAS Transparency Committee evidence research	Core capability	Analytics inputs only	Partial	No	Desk research only
ASMR comparative claim testing	Yes	Limited	Limited	No	No
SMR reimbursement and rate research	Yes	Partial	Limited	No	No
CEPS price negotiation preparation	Yes	Partial	No	No	No
Hospital formulary and medicines committee research	Yes	Via hospital data	Limited	No	No
Prescriber U&A and segmentation	Core capability	Limited — data-led	Yes — panel-based	Database only	None
KOL identification and influence mapping	Yes	Data-driven targeting	Partial	Reference data only	Profiles only
French-language instruments and moderation	Yes — native	Standard	Standard	French data only	No fieldwork

What Decides Pharmaceutical Research Quality in France

The ASMR Is a Comparative Verdict, and Comparative Evidence Is Rarely Improvised

The Transparency Committee awards the ASMR by judging improvement against existing therapy, and that judgement is only as strong as the comparative evidence available. A trial programme designed against placebo, or against a comparator that French practice has moved past, produces an improvement claim the Committee has little basis to accept, and no amount of post-hoc research will repair it. The research that changes ASMR outcomes is commissioned while the evidence plan is still open: testing which comparator French clinicians regard as the real standard of care, which endpoints they consider clinically meaningful, and where an improvement argument will be seen as marginal.

SMR and ASMR Answer Different Questions and Need Different Research

The SMR determines whether a medicine is reimbursed and at what rate, resting on severity of condition, efficacy and safety, and place in the therapeutic strategy. The ASMR determines pricing leverage and rests on demonstrated improvement over comparators. A strong SMR with a weak ASMR yields a reimbursed product with little pricing headroom, which is a common and avoidable French outcome. Research programmes that treat French access as a single dossier exercise tend to build one argument and assume it serves both purposes; it does not, and the commercial cost of that shortcut lands on price.

National Reimbursement Does Not Get You Into the Hospital

For hospital-administered medicines, national reimbursement status is necessary but not sufficient: hospital pharmacists and institutional medicines committees decide what is actually stocked, protocolled and used, and their reasoning concerns budget impact within the institution, preparation and administration burden, and fit with existing protocols rather than the national assessment. Research that samples only prescribing clinicians and never the hospital pharmacy and committee layer routinely over-predicts uptake in exactly the therapy areas — oncology, haematology, immunology — where hospital control is strongest.

Frequently Asked Questions

Who is the top pharmaceutical market research company in France?

For custom primary pharmaceutical research, BioNixus is the leading choice in France — it runs HAS Transparency Committee evidence work, ASMR comparative claim testing and separate SMR research, CEPS price negotiation preparation, hospital formulary and medicines committee studies, prescriber U&A and brand tracking, KOL identification and influence mapping, and HEOR and budget impact evidence, with French-language instruments and moderation. For syndicated prescription data and national health data analytics, IQVIA France is the established source. Ipsos Healthcare, Cegedim and GlobalData serve narrower needs: therapy-area monitors and chart audits, healthcare professional reference data and CRM, and pipeline intelligence respectively.

What does pharmaceutical market research cost in France?

Custom pharmaceutical primary research in France typically starts around €20,000 for a focused qualitative study and rises to €70,000 or more for multi-stakeholder programmes combining prescriber, payer and hospital formulary research. Cost is driven mainly by sample difficulty: interviews with senior specialists at university hospital centres, hospital pharmacists and payer-facing advisers command materially higher fees per completed interview than office-based general practitioners. French-language instrument development and native moderation add cost relative to fielding a translated global questionnaire, but they are what makes the output usable. Syndicated subscriptions are cheaper and answer different questions.

What is HAS and how does it affect pharmaceutical market research in France?

The Haute Autorité de Santé is the French health authority whose Transparency Committee assesses new medicines for reimbursement. It awards an SMR rating covering clinical usefulness, which governs reimbursement status and rate, and an ASMR rating covering improvement over existing comparators, which governs pricing leverage with the CEPS. Because both ratings rest on evidence that is largely fixed by submission, research designed to influence a French outcome runs beforehand: establishing the comparator French practice regards as standard of care, testing which endpoints support a credible improvement claim, and identifying where the Committee is likely to push back.

What is the difference between SMR and ASMR?

The SMR, service médical rendu or actual benefit, assesses whether a medicine is clinically useful enough to be reimbursed and at what rate, weighing severity of the condition, efficacy and safety, and place in the therapeutic strategy. The ASMR, amélioration du service médical rendu, is a comparative rating measuring improvement over existing therapy on a scale running from major improvement to none, and it is the rating that determines pricing leverage in negotiation with the CEPS. A medicine can secure reimbursement on the strength of its SMR while a weak ASMR leaves it with almost no room to negotiate a premium.

How does the CEPS set prices in France?

The Comité Économique des Produits de Santé negotiates price with the manufacturer after the Transparency Committee has issued its ratings. The negotiation is anchored on the ASMR outcome, the cost of relevant comparators, prices in other European markets and expected volumes, and agreements routinely include volume-related conditions and rebates, so the published price and the realised net price differ. Where an improvement claim is significant and the budget consequences material, an economic evaluation may also be required. Pricing research in France therefore has to be framed around what the comparative claim can sustain, not around a standalone price point.

What role does ANSM play, including early access?

The Agence nationale de sécurité du médicament et des produits de santé is the French regulator, granting marketing authorisation for nationally licensed products alongside the EU centralised route and overseeing safety surveillance. It also administers early access and compassionate use schemes that can make a medicine available to patients with serious conditions ahead of a formal reimbursement decision. These routes are commercially and clinically significant, and research supporting them differs from reimbursement research: the questions concern eligible populations, prescriber willingness to initiate under early access conditions, and how early-use experience will shape the later Transparency Committee assessment.

How is pharmaceutical research different from healthcare market research in France?

Healthcare market research covers the broader system — hospitals and providers, medical devices, digital health, patient experience and consumer health. Pharmaceutical market research is narrower and deeper: it centres on prescription medicines and the mechanics that govern them in France, meaning ANSM authorisation and early access, HAS Transparency Committee assessment with its SMR and ASMR ratings, CEPS price negotiation, Assurance Maladie reimbursement rates, hospital formulary listing, prescriber usage and attitudes, brand and message tracking, KOL influence, and payer value arguments supported by HEOR and budget impact evidence. Teams launching or defending a prescription medicine need the pharmaceutical-specific version.

Does BioNixus conduct pharmaceutical market research in France?

Yes. BioNixus delivers custom pharmaceutical market research across France for pharmaceutical and biotech clients, including HAS Transparency Committee evidence work, ASMR comparative claim testing and SMR research, CEPS price negotiation preparation, hospital formulary and medicines committee studies, prescriber U&A and brand tracking, KOL identification and influence mapping across university hospital centres, patient journey mapping, and HEOR and budget impact evidence. Instruments are authored in French with native-French moderation, bilingual reporting, and healthcare professional engagement consistent with French transparency requirements. Contact us to discuss a French pharmaceutical research scope.

Related Resources

Top Healthcare Market Research Companies in France

Top Pharmaceutical Market Research Companies in the UK

Top Pharmaceutical Market Research Companies in Germany

Top Pharmaceutical Market Research Companies in Italy

Top Pharmaceutical Market Research Companies in Spain

Request a France Pharmaceutical Research Proposal

Plan Pharmaceutical Market Research in France

BioNixus runs custom pharmaceutical research across France — HAS Transparency Committee evidence, ASMR comparative claim research, CEPS pricing preparation, hospital formulary studies, prescriber U&A and brand tracking, KOL mapping and HEOR, with French-language fieldwork.

Request a Proposal